Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis.
Leptin is a peptide hormone which acts on cells of immune system by influencing the production of cytokines. Serum leptin levels and cytokine production by peripheral blood mononuclear cells (PBMC) were measured in 18 secondary progressive multiple sclerosis (SPMS) patients under IFN-beta-1b treatment. There were no overall effects on leptin, interleukin-6 (IL-6), IL-10 and IL-12 p40 after 2, 6 and 12 months of treatment. However, leptin and IL-6 decreased after 6 and 12 months of treatment in 12 patients who did not show progression of disability. Thus, our pilot data show that the beneficial effect of IFN-beta on some SPMS patients might be associated with the reduced levels of leptin and reduced IL-6 production by PBMC.
Angelucci
Francesco
F
Institute of Neurology, Department of Neuroscience, Catholic University, Largo Gemelli 8, 00168 Rome, Italy.
Mirabella
Massimiliano
M
Caggiula
Marcella
M
Frisullo
Giovanni
G
Patanella
Katia
K
Sancricca
Cristina
C
Nociti
Viviana
V
Tonali
Pietro Attilio
PA
Batocchi
Anna Paola
AP
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis*; D020738:Leptin / Q000097:blood*; D007963:Leukocytes, Mononuclear / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000378:metabolism*; D010865:Pilot Projects; D011237:Predictive Value of Tests
D007155:Immunologic Factors; D015850:Interleukin-6; D020738:Leptin; D016899:Interferon-beta